# A Multicenter, Open-label, Randomized Clinical Study to Assess Efficacy and Safety of 3 Doses of Myrcludex B for 24 Weeks in Combination With Tenofovir Compared to Tenofovir Alone to Suppress HBV Replication in Patients With Chronic Hepatitis D

> **NCT03546621** · PHASE2 · COMPLETED · sponsor: **Hepatera Ltd.** · enrollment: 120 (actual)

## Conditions studied

- Chronic Hepatitis D Infection With Hepatitis B

## Interventions

- **DRUG:** Myrcludex B
- **DRUG:** Myrcludex-B
- **DRUG:** Myrcludex-B
- **DRUG:** Tenofovir

## Key facts

- **NCT ID:** NCT03546621
- **Lead sponsor:** Hepatera Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-02-16
- **Primary completion:** 2018-01-31
- **Final completion:** 2018-01-31
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2021-05-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03546621

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03546621, "A Multicenter, Open-label, Randomized Clinical Study to Assess Efficacy and Safety of 3 Doses of Myrcludex B for 24 Weeks in Combination With Tenofovir Compared to Tenofovir Alone to Suppress HBV Replication in Patients With Chronic Hepatitis D". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT03546621. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*